Get the Stockscreener App
88.82
1.04%
0.91
After Hours:
88.11
-0.71
-0.80%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $88.82, with a volume of 11.69M.
It is up +1.04% in the last 24 hours and down -8.25% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$87.91
Open:
$88.36
24h Volume:
11.69M
Relative Volume:
0.98
Market Cap:
$154.71B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
24.74
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+5.30%
1M Performance:
-8.25%
6M Performance:
-29.59%
1Y Performance:
-34.47%
1-Day Range:
$87.41
$89.34
1-Week Range:
$82.69
$89.34
52-Week Range:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
88.82 | 153.12B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
317.75 | 120.08B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.58 | 99.27B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.81 | 83.12B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.16 | 47.44B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Spinal Cord Stimulator Problems Resulted in Severe Paralysis: Lawsuit - AboutLawsuits.com
Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings - Yahoo Finance
Abbott Laboratories stock (US0028241000): steady momentum after latest earnings and diabetes tech pu - AD HOC NEWS
Has The Recent Slide In Abbott Laboratories (ABT) Opened Up A Valuation Opportunity? - simplywall.st
A Look at Abbott Laboratories (ABT) After 4.1% Gain -- GF Value $127.69 vs Price $87.91 - GuruFocus
Has the Abbott Laboratories sell-off finally created an entry point? - MSN
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know - TradingKey
Boston Scientific Bets on Growth Through Strategic M&A Deals - TradingView
Raised full-year 2026 outlook lifts Abbott stock 3.18% - Traders Union
Trump’s stock trading spree included North Chicago’s Abbott Labs - Crain's Chicago Business
Abbott stock posts modest gain amid fragile momentum below MA-20 resistance: weekly review - Traders Union
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now? - TradingView
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Thrivent Financial for Lutherans Acquires 48,286 Shares of Abbott Laboratories $ABT - MarketBeat
North Dakota State Investment Board Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) Stock Analysis: Unlocking a 40% Potential Upside for Savvy Investors - DirectorsTalk Interviews
Abbott Laboratories $ABT Shares Purchased by Cambridge Investment Research Advisors Inc. - MarketBeat
Abbott Laboratories stock (US0028241000): Q1 2026 growth, guidance raise and diabetes momentum - AD HOC NEWS
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Abbott Laboratories stock (US0028241000): diabetes growth and fresh guidance keep investors focused - AD HOC NEWS
Abbott Laboratories Stock (ABT) Opinions on Recent Price Declines - Quiver Quantitative
Abbott Laboratories stock (US0028241000): diabetes segment drives attention after latest quarterly u - AD HOC NEWS
Abbott Laboratories $ABT Stock Holdings Lowered by iA Global Asset Management Inc. - MarketBeat
AlphaCore Capital LLC Increases Stock Position in Abbott Laboratories $ABT - MarketBeat
Abacus Wealth Partners LLC Buys 12,260 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Trade Ideas — LSX:850103 - TradingView
Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment - simplywall.st
Commerzbank Aktiengesellschaft FI Sells 131,572 Shares of Abbott Laboratories $ABT - MarketBeat
Bessemer Group Inc. Sells 213,665 Shares of Abbott Laboratories $ABT - MarketBeat
ABT (NYSE: ABT) Form 144 shows 7,587 RSU shares and prior 29,211 sale - Stock Titan
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Is Abbott’s Exact Sciences Deal And Nutrition Pivot Altering The Investment Case For Abbott (ABT)? - Yahoo Finance
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
Is the options market predicting a spike in Abbott Laboratories stock? - MSN
Abbott Laboratories stock (US0028241000): Q1 beat, Exact Sciences deal and legal risks keep investor - AD HOC NEWS
Abbott class action alleges FreeStyle Libre 2 glucose monitor is defective - Class Action Lawsuits
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up - Yahoo Finance
Phoenix Financial Ltd. Increases Stock Position in Abbott Laboratories $ABT - MarketBeat
Summit Wealth Group LLC Co. Sells 21,449 Shares of Abbott Laboratories $ABT - MarketBeat
Conning Inc. Grows Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) Short Interest & Short Float | Updated May 2026 $ABT - MarketBeat
Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT) - simplywall.st
NEC Baby Formula Lawsuit & Settlement | May 2026 Update - Lawsuit Information Center
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
ABT Stock Quote Price and Forecast - CNN
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B - AD HOC NEWS
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment - Insider Monkey
Abbott Laboratories stock (US0028241000): shares rebound after earnings and guidance update - AD HOC NEWS
Insider trades: Okta and Abbott see buys, Micron insiders sell - MSN
What to know about Kyle Diamantas, the new acting FDA commissioner - The Guardian
How The Investment Narrative For Abbott Laboratories (ABT) Is Shifting With Recent Analyst Resets - Yahoo Finance
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):